| Literature DB >> 30469413 |
Ewa Brągoszewska1, Izabela Biedroń2.
Abstract
The aims of this article are to characterize: the quantity of culturable bacterial aerosol (QCBA) and the quality of culturable bacterial aerosol (QlCBA) in an office building in Southern Poland during the spring. The average concentration of culturable bacterial aerosol (CCBA) in this building ranged from 424 CFU m-3 to 821 CFU m-3, below Polish proposals for threshold limit values. Size distributions were unimodal, with a peak of particle bacterial aerodynamic diameters less than 3.3 μm, increasing potentially adverse health effects due to their inhalation. The spring office exposure dose (SPED) of bacterial aerosol was estimated. The highest value of SPED was in April (218 CFU kg-1), whereas the lowest was in June (113 CFU kg-1). Analysis was undertaken to determine the antibiotic resistance of isolated strains and their ability to form biofilms, which may facilitate the spread of antibiotic resistance genes. In the course of the study, it was found that Staphylococcus xylosus had the greatest ability to form biofilms, while the strains with the highest antibiotic resistance were Micrococcus luteus D and Macrococcus equipercicus. Given that mainly antibiotic-sensitive bacteria from bioaerosol were isolated, which transfers resistance genes to their plasmids, this shows the need for increased monitoring of indoor air quality in workplaces.Entities:
Keywords: antibiotic resistance; bioaerosol; health risk assessment; indoor air quality; size distribution
Mesh:
Substances:
Year: 2018 PMID: 30469413 PMCID: PMC6267043 DOI: 10.3390/ijerph15112604
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Sampling site location (Map data: 2017© Google, ORION-ME; https://commons.wikimedia.org).
Descriptive statistics of indoor air quality (IAQ) environmental conditions in office building by month during sample collection.
| Environmental Parameters, Mean ± SD 1 | ||||
|---|---|---|---|---|
| Month | Indoor Temperature, °C | Indoor Relative Humidity (RH), % | Outdoor Temperature, °C | Outdoor Relative Humidity (RH), % |
| March | 19.2 ± 4.1 | 31.2 ± 2.1 | 14.1 ± 1.1 | 76.0 ± 12.7 |
| April | 19.8 ± 6.1 | 34.8 ± 3.2 | 16.4 ± 2.1 | 77.8 ± 11.2 |
| May | 23.2 ± 6.4 | 32.4 ± 4.0 | 19.1 ± 3.2 | 72.6 ± 12.6 |
| June | 24.1 ± 6.2 | 30.2 ± 2.2 | 22.2 ± 2.4 | 71.6 ± 8.1 |
1 SD—Standard deviation.
Antibiotics used in susceptibility test.
| Group of Antibiotics | Antibiotic | Dose (mg) |
|---|---|---|
| Aminocoumarin | Novobiocin | 30 |
| Amikacin | 30 | |
| Gentamicin | 120 | |
| Gentamicin | 200 | |
| Neomycin | 30 | |
| Netilmicin | 30 | |
| Tobramycin | 30 | |
| Carbapenems | Doripenem | 10 |
| Ertapenem | 10 | |
| Imipenem | 10 | |
| Cephalosporins | Cefaclor | 30 |
| Cefadroxil | 30 | |
| Cefepime | 30 | |
| Cefoxitin | 30 | |
| Ceftaroline | 5 | |
| Ceftazidime | 30 | |
| Drugs against mycobacteria | Rifampicin | 30 |
| Glycopeptides | Teicolpanin | 30 |
| Vancomycin | 30 | |
| Macrolides | Azithromycin | 15 |
| Erythromycin | 30 | |
| Monobactams | Aztreonam | 30 |
| Nitrofurans | Nitrofurantoin | 300 |
| others | Metronidazole | 50 |
| Mupirocin | 200 | |
| Trimethoprim | 5 | |
| Penicillins | Amoxycillin | 30 |
| Ampicillin | 25 | |
| Piperacillin | 100 | |
| Ticarcillin | 75 | |
| Quinolones/Fluoroquinolones | Ciprofloxacin | 10 |
| Nalidixic acid | 30 | |
| Norfloxacin | 10 | |
| Ofloxacin | 5 | |
| Sulfonamides | Trimethoprim/sulph | 25 |
| Tetracyclines | Doxycycline | 30 |
| Minocycline | 30 |
The primers used in the PCR reaction and size of the amplicons.
| Target | Primer | Sequence (5’ to 3’) | Amplicon Size (bp) |
|---|---|---|---|
|
| aacA-aphD1 | TAA TCC AAG AGC AAT AAG GGC | 227 |
|
| ermA1 | AAG CGG TAA ACC CCT CTG A | 190 |
|
| tekK1 | GTA GCG ACA ATA GGT AAT AGT | 360 |
|
| mecA1 | AAA ATC GAT GGT AAA GGT TGG C | 532 |
|
| varB1 | GCT GCG AAT TCA GTT GTT ACA | 136 |
Average concentrations of culturable bacterial aerosol (CCBA) in offices (CFU m−3).
| Month | CCBA | SD 1 | CCBA max | CCBA min |
|---|---|---|---|---|
| March | 786 | 118.14 | 852 | 289 |
| April | 821 | 141.21 | 946 | 324 |
| May | 582 | 117.47 | 774 | 126 |
| June | 424 | 96.24 | 581 | 114 |
| Average spring CCBA | 653.25 | 118.26 | 788.25 | 213.25 |
1 SD—Standard deviation.
Figure 2Size distribution of the bacterial aerosol in the offices indoor air. Dae—aerodynamic diameter; ΔC—concentration of bacterial aerosol on particular stage of 6-stage Andersen impactor; Ctotal—total concentration of bacterial aerosol; Δ log Dae—logarithm of differences of cut-off diameters for particular stage of 6-stage Andersen Impactor.
Calculated exposure dose spring office exposure dose (SPED) of bacterial aerosol inhaled by staff of office building in four months of spring season.
| Month | SPED—Office Building Exposure Dose (CFU kg−1) |
|---|---|
| March | 210 |
| April | 218 |
| May | 155 |
| June | 113 |
| Average SPED | 174 |
Species of bacteria isolated from indoor office air.
| Species of Isolated Bacteria |
|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antibiotic resistance pattern on disk diffusion method.
| Bacteria | Antibiotics Resistance |
|---|---|
|
| Vancomycin, Azithromycin, Erythromycin, Aztreonam, Nitrofurantoin, Metronidazole, Mupirocin, Ticarcillin, Nalidixic acid, Norfloxacin |
|
| Neomycin, Tobramycin, Ertapenem, Imipenem, Cefaclor, Cefadroxil, Cefepime, Cefoxitin, Ceftazidime, Teicolpanin, Azithromycin, Erythromycin, Aztreonam, Metronidazole, Trimethoprim, Amoxycillin, Ampicillin, Piperacillin, Ticarcillin, Nalidixic acid |
|
| Amikacin, Gentamicin, Doripenem, Imipenem, Cefaclor, Cefepime, Ceftaroline, Rifampicin, Azithromycin, Erythromycin, Aztreonam, Metronidazole, Amoxycillin, Ampicillin, Ofloxacin |
|
| Doripenem, Ertapenem, Cefaclor, Cefadroxil, Cefepime, Cefoxitin, Ceftaroline, Ceftazidime, Erythromycin, Aztreonam, Metronidazole, Ciprofloxacin, Nalidixic acid, Doxycycline |
|
| Doripenem, Ertapenem, Cefaclor, Cefadroxil, Cefepime, Cefoxitin, Ceftaroline, Ceftazidime, Teicolpanin, Nitrofurantoin, Metronidazole, Mupirocin, Trimethoprim, Amoxycillin, Ampicillin, Piperacillin, Ticarcillin, Norfloxacin, Trimethoprim/sulph |
|
| Aztreonam, Metronidazole, Nalidixic acid |
|
| Amikacin, Neomycin, Netilmicin, Tobramycin, Ertapenem, Cefadroxil, Cefepime, Cefoxitin, Ceftazidime, Azithromycin, Erythromycin, Aztreonam, Metronidazole |
Figure 3Biofilm formation by the isolated strains. Bars represent the standard deviation.
Figure 4Multiplex PCR of plasmid DNA: Lane I–VII strains (I—Gemella haemolysans; II—Macrococcus equipercicus; III—Macrococcus brunensis; IV—Bacillus cereus; V—Micrococcus luteus D; VI—Staphylococcus xylosus; VII—Enterococcus faecium), lane C: negative control - without template DNA; lane M: 100bp DNA ladder. Line 1–5 indicate the size of the amplification products:1-vatB (136bp), 2-ermA (190bp), 3-aacA-aphD (227bp), 4-tekK (360bp), 5-mecA (532bp).